The content on this site is intended for healthcare professionals only
Dr Ribero speaks with ecancer at EADO 2017 about the prognostic and diagnostic value of histologic regression in predicting and tracking immune response to skin cancers.
He notes improved tumour infiltration by patients with regressed melanoma, and considers how this may guide immunotherapy treatments in the future.
Dr Ribero also raises discussion about the role of nevi in regression.
ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.
SABCS 2025: Latest developments in multigene testing in early breast cancer
Digital pathology superior to manual SP263 PD-L1 TC scoring for stage II-IIIA high PD-L1 expression NSCLC
Predicting tumour mutations from pathology images may help increase personalised medicine utilisation
ESMO 2024: Optimising the personalisation of prostate cancer treatment
SABCS 2023: Latest breast cancer diagnostics guidelines
Adjuvant radiotherapy has no benefit following radical prostatectomy
OncoAlert Round Up for August 25th - 31st, 2023
Choosing Wisely in pathology
Choosing Wisely in radiology Tanzania
